Close Menu

NEW YORK – Elicio Therapeutics said on Wednesday it has raised $73 million in a Series B financing round and that it will use the funds to advance its lead candidate, ELI-002, into clinical trials this year.

The company did not disclose specific investors that contributed to this funding round, but said the financing came from an "international investor base, including multiple strategic and institutional investors."

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.